Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
- Launching into this growth market1 as part of the company's geographic expansion strategy
- Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the launch of Nuceiva® (prabotulinumtoxinA).
Nuceiva® is approved by the Therapeutic Goods Administration (TGA) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients2.
"Launching Evolus in Australia underscores our commitment to strategic geographic expansion and our dedicated focus on customers in this growth market," said David Moatazedi, President and Chief Executive Officer. "This milestone fuels our global growth strategy by establishing a strong presence in a key region. Successfully entering new markets like Australia positions us for sustained above-market growth, reinforcing Evolus' position as a global leader in its industry."
Evolus has established a direct operating entity in Australia, under the leadership of Daniel Henry. Working closely with aesthetics healthcare professionals will enable Evolus to offer this new treatment to patients. Nuceiva® is licensed in the United States under the brand name Jeuveau® and has been the fastest-growing neurotoxin in the United States for three consecutive years*.
"As the beauty and healthcare landscape continues to evolve, we understand the importance of working closely with our customers and partners to navigate these changes successfully," said Dan Stewart, Vice President and General Manager of Evolus International. "I have full confidence in Daniel Henry, who brings a wealth of experience and vision to our team. We are dedicated to supporting Australian healthcare professionals by providing exceptional customer service, innovative educational initiatives, and a user-friendly online service platform to help evolve their practices and continually deliver outstanding patient satisfaction."
"Beauty in Australia is evolving as younger generations get curious about non-surgical enhancement and rejuvenation options," said Dr. Steven Liew, renowned Plastic Surgeon and Medical Director at Shape Clinic in Sydney. "With their unapologetically millennial focus, I'm excited to be working with Evolus as they expand to Australia. By offering aesthetics healthcare professionals more choice, practitioners like me will be able to deliver optimal outcomes tailored to each patient's evolving beauty preferences and needs."
The safety and efficacy of Nuceiva® has been evaluated through the company's TRANSPARENCY clinical program – three Phase III trials3,4 including the largest head-to-head aesthetic pivotal study versus Botox® (onabotulinumtoxinA) to date, and two long-term safety studies5,6. Side effects were similar to others in this class of medicine. For the full list of adverse events, warnings and contraindications consult the Nuceiva® Prescribing Information.
About Evolus, Inc.
Evolus (NASDAQ:EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Forward Looking Statements
This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements that relate to the status of regulatory processes, future plans, events, prospects or performance and statements containing the words "plans," "expects," "believes," "strategy," "opportunity," "anticipates," "outlook," "designed," or other forms of these words or similar expressions, although not all forward-looking statements contain these identifying words. The company's forward-looking statements include, but are not limited to, statements related to the company's prospects, geographical expansion, milestones and programs.
Forward-looking statements involve risks and uncertainties that could cause actual results or experiences to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with our ability to address all of our losses, costs, expenses, liabilities and damages resulting from the settlement agreement with Daewoong and our ability to comply with the terms and conditions in the Allergan/Medytox Settlement Agreements, the continued impact of COVID-19 on our business and the economy generally, uncertainties related to customer and consumer adoption of Nuceiva® / Jeuveau®, the efficiency and operability of our digital platform or commercialization strategies, competition and market dynamics, and our ability to maintain regulatory approval of Nuceiva® / Jeuveau® and other risks described in Evolus' filings with the Securities and Exchange Commission, including in the section entitled "Risk Factors" in our in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission on May 7, 2024. These filings can be accessed online at www.sec.gov. Except as required by law, Evolus undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If the company does update or revise one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Botox® (Botulinum toxin type A) is a registered trademark of Allergan, Inc.
References:
- Decision Research Group (DRG) Aesthetic Injectables Market Insights, Europe, July 2023. Data on file
- https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-PI-01255-1&d=20240723172310101 (Accessed 23/07/24)
- Berthold-Josef Rzany, MD, ScM et al. Aesthetic Surgery Journal, 2019, 1–16
- Kenneth R. Beer et al. Dermatol Surgery 2019; 45 (11); 1381 – 1393
- Joely Kaufman-Janette, MD et al. Aesthetic Surgery Journal 2021, 1–14
- Z. Paul Lorenc, MD, FACS et al. Aesthetic Surgery Journal 2021, 1–16
* Measured by comparing year-over-year revenue growth of each aesthetic neurotoxin on the market for the entirety of each comparable year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730657453/en/